The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer
The objectives of this study are to confirm the safety and efficacy of FCH-PET/CT and to
establish our ability to reproduce results from the literature using FCH-PET/CT as a
diagnostic and decision making tool in the management in two predefined groups of prostate
cancer patients, specifically, biochemical recurrence and high risk staging. The primary
endpoints of the study are the incidence of adverse events (AE) in the study population up
to 24 hours following the scan, and the sensitivity and specificity of FCH-PET/CT vs CT on a
per-patient and per-lesion basis.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society